NASDAQ:PETX - Aratana Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aratana Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.92 0.00 (0.00 %) (As of 07/18/2019) Add Compare Today's Range$4.92Now: $4.92▼$4.9250-Day Range$4.92MA: $4.92▼$4.9252-Week Range$3.30Now: $4.92▼$7.16VolumeN/AAverage Volume1.03 million shsMarket Capitalization$241.08 millionP/E RatioN/ADividend YieldN/ABeta1.4 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PETX Previous Symbol CUSIPN/A CIK1509190 Webhttp://www.aratana.com/ Phone913-353-1000Debt Debt-to-Equity RatioN/A Current Ratio6.66 Quick Ratio5.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$35.41 million Price / Sales6.81 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book2.38Profitability EPS (Most Recent Fiscal Year)($0.32) Net Income$-14,720,000.00 Net Margins-33.47% Return on Equity-12.99% Return on Assets-10.82%Miscellaneous Employees83 Outstanding Shares49,000,000Market Cap$241.08 million Next Earnings Date3/10/2020 (Estimated) OptionableOptionable Receive PETX News and Ratings via Email Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter. Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions What is Aratana Therapeutics' stock symbol? Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX." How were Aratana Therapeutics' earnings last quarter? Aratana Therapeutics Inc (NASDAQ:PETX) released its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company earned $21.56 million during the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative return on equity of 12.99%. View Aratana Therapeutics' Earnings History. When is Aratana Therapeutics' next earnings date? Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Aratana Therapeutics. What price target have analysts set for PETX? 2 brokers have issued 1 year price objectives for Aratana Therapeutics' shares. Their forecasts range from $4.76 to $5.00. On average, they expect Aratana Therapeutics' share price to reach $4.88 in the next year. This suggests that the stock has a possible downside of 0.8%. View Analyst Price Targets for Aratana Therapeutics. What is the consensus analysts' recommendation for Aratana Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aratana Therapeutics. Has Aratana Therapeutics been receiving favorable news coverage? Media headlines about PETX stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aratana Therapeutics earned a daily sentiment score of -4.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Aratana Therapeutics. Who are some of Aratana Therapeutics' key competitors? Some companies that are related to Aratana Therapeutics include Cytokinetics (CYTK), Achillion Pharmaceuticals (ACHN), Stoke Therapeutics (STOK), I-Mab (ARQT), Phathom Pharmaceuticals (PHAT), Radius Health (RDUS), Endonovo Therapeutics (ENDV), Amphastar Pharmaceuticals (AMPH), ImmunoGen (IMGN), Homology Medicines (FIXX), Dova Pharmaceuticals (DOVA), AVEO Pharmaceuticals (AVEO), Collegium Pharmaceutical (COLL), Rhythm Pharmaceuticals (RYTM) and ANI Pharmaceuticals (ANIP). What other stocks do shareholders of Aratana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aratana Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Celldex Therapeutics (CLDX), Corcept Therapeutics (CORT), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Pieris Pharmaceuticals (PIRS), Aurinia Pharmaceuticals (AUPH), Micron Technology (MU), Progenics Pharmaceuticals (PGNX) and Corbus Pharmaceuticals (CRBP). Who are Aratana Therapeutics' key executives? Aratana Therapeutics' management team includes the folowing people: Mr. Craig A. Tooman, Pres, CEO & Board Director (Age 53)Ms. Rhonda L. Hellums, CFO & Treasurer (Age 47)Mr. John C. Ayres J.D., VP of Corp. Devel. and Admin., Gen. Counsel & Sec. (Age 40)Mr. Brent A. Standridge, Consultant (Age 61)Ms. Rachel Reiff, Head of Corp. Communications What is Aratana Therapeutics' stock price today? One share of PETX stock can currently be purchased for approximately $4.92. How big of a company is Aratana Therapeutics? Aratana Therapeutics has a market capitalization of $241.08 million and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe.View Additional Information About Aratana Therapeutics. What is Aratana Therapeutics' official website? The official website for Aratana Therapeutics is http://www.aratana.com/. How can I contact Aratana Therapeutics? Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected] MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 405 (Vote Outperform)Underperform Votes: 280 (Vote Underperform)Total Votes: 685MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: Why are analyst ratings important in trading stocks?
